Recenti progressi nel trattamento medico del carcinoma della mammella

Translated title of the contribution: Recent progress in the medical treatment of breast carcinoma

A. D'Alessio, A. Fabi, P. Papaldo, F. Cognetti

Research output: Contribution to journalArticle

Abstract

Neoadjuvant (preoperative) chemotherapy is a therapeutic choice in operable locally advanced breast carcinoma. It is administered with the aim of obtaining several advantages: to increase conservative surgery, which becomes possible in 82-95% of cases, to reduce local recurrences and to prolong overall survival. Hormone therapy and chemotherapy added to local radical treatment favorably alter the natural history of breast cancer: randomized trials have indicated that the reduction in recurrence and death rates is statistically significant for pre- and post-menopausal women. The reduction in recurrence rate is of 35 and 20% respectively in women <50 years and in older women. The reduction in mortality rate is 27 and 11% respectively in the same category. Guidelines for the adjuvant treatment has been better through the definition of different risk categories on the basis of prognostic factors, such as dimension of primitive, lymph node involvement, estrogen- and progesteron-receptor expression, and age. Ongoing trials should help verify if prognosis of lymph node negative patients could be improved by the use of anthracyclines in the adjuvant setting, as well as in lymph node positive patients. Regarding the treatment of metastatic disease, the availability of new drugs, like paclitaxel, docetaxel and vinorelbine, obtained good rates in terms of responses (50-80% and 40-60% in first and second line chemotherapy respectively), associated with a benefit in quality of life. Actually the clinical and biological research wants to identify the synergism between available drugs and new hormonal or cytotoxic molecules and to introduce new biological modulators of the response in the clinical practice.

Original languageItalian
JournalAnnali Italiani di Medicina Interna, Supplement
Volume14
Issue number1
Publication statusPublished - 1999

Fingerprint

Breast Neoplasms
Lymph Nodes
docetaxel
Recurrence
Drug Therapy
Therapeutics
Mortality
Anthracyclines
Progesterone Receptors
Paclitaxel
Estrogen Receptors
Pharmaceutical Preparations
Quality of Life
Hormones
Guidelines
Survival
Research

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Recenti progressi nel trattamento medico del carcinoma della mammella. / D'Alessio, A.; Fabi, A.; Papaldo, P.; Cognetti, F.

In: Annali Italiani di Medicina Interna, Supplement, Vol. 14, No. 1, 1999.

Research output: Contribution to journalArticle

@article{b84cf7cb76f8405f8a541b1c1a0fb54b,
title = "Recenti progressi nel trattamento medico del carcinoma della mammella",
abstract = "Neoadjuvant (preoperative) chemotherapy is a therapeutic choice in operable locally advanced breast carcinoma. It is administered with the aim of obtaining several advantages: to increase conservative surgery, which becomes possible in 82-95{\%} of cases, to reduce local recurrences and to prolong overall survival. Hormone therapy and chemotherapy added to local radical treatment favorably alter the natural history of breast cancer: randomized trials have indicated that the reduction in recurrence and death rates is statistically significant for pre- and post-menopausal women. The reduction in recurrence rate is of 35 and 20{\%} respectively in women <50 years and in older women. The reduction in mortality rate is 27 and 11{\%} respectively in the same category. Guidelines for the adjuvant treatment has been better through the definition of different risk categories on the basis of prognostic factors, such as dimension of primitive, lymph node involvement, estrogen- and progesteron-receptor expression, and age. Ongoing trials should help verify if prognosis of lymph node negative patients could be improved by the use of anthracyclines in the adjuvant setting, as well as in lymph node positive patients. Regarding the treatment of metastatic disease, the availability of new drugs, like paclitaxel, docetaxel and vinorelbine, obtained good rates in terms of responses (50-80{\%} and 40-60{\%} in first and second line chemotherapy respectively), associated with a benefit in quality of life. Actually the clinical and biological research wants to identify the synergism between available drugs and new hormonal or cytotoxic molecules and to introduce new biological modulators of the response in the clinical practice.",
author = "A. D'Alessio and A. Fabi and P. Papaldo and F. Cognetti",
year = "1999",
language = "Italian",
volume = "14",
journal = "Annali Italiani di Medicina Interna, Supplement",
issn = "1122-0538",
publisher = "Italian Inner Medicine society",
number = "1",

}

TY - JOUR

T1 - Recenti progressi nel trattamento medico del carcinoma della mammella

AU - D'Alessio, A.

AU - Fabi, A.

AU - Papaldo, P.

AU - Cognetti, F.

PY - 1999

Y1 - 1999

N2 - Neoadjuvant (preoperative) chemotherapy is a therapeutic choice in operable locally advanced breast carcinoma. It is administered with the aim of obtaining several advantages: to increase conservative surgery, which becomes possible in 82-95% of cases, to reduce local recurrences and to prolong overall survival. Hormone therapy and chemotherapy added to local radical treatment favorably alter the natural history of breast cancer: randomized trials have indicated that the reduction in recurrence and death rates is statistically significant for pre- and post-menopausal women. The reduction in recurrence rate is of 35 and 20% respectively in women <50 years and in older women. The reduction in mortality rate is 27 and 11% respectively in the same category. Guidelines for the adjuvant treatment has been better through the definition of different risk categories on the basis of prognostic factors, such as dimension of primitive, lymph node involvement, estrogen- and progesteron-receptor expression, and age. Ongoing trials should help verify if prognosis of lymph node negative patients could be improved by the use of anthracyclines in the adjuvant setting, as well as in lymph node positive patients. Regarding the treatment of metastatic disease, the availability of new drugs, like paclitaxel, docetaxel and vinorelbine, obtained good rates in terms of responses (50-80% and 40-60% in first and second line chemotherapy respectively), associated with a benefit in quality of life. Actually the clinical and biological research wants to identify the synergism between available drugs and new hormonal or cytotoxic molecules and to introduce new biological modulators of the response in the clinical practice.

AB - Neoadjuvant (preoperative) chemotherapy is a therapeutic choice in operable locally advanced breast carcinoma. It is administered with the aim of obtaining several advantages: to increase conservative surgery, which becomes possible in 82-95% of cases, to reduce local recurrences and to prolong overall survival. Hormone therapy and chemotherapy added to local radical treatment favorably alter the natural history of breast cancer: randomized trials have indicated that the reduction in recurrence and death rates is statistically significant for pre- and post-menopausal women. The reduction in recurrence rate is of 35 and 20% respectively in women <50 years and in older women. The reduction in mortality rate is 27 and 11% respectively in the same category. Guidelines for the adjuvant treatment has been better through the definition of different risk categories on the basis of prognostic factors, such as dimension of primitive, lymph node involvement, estrogen- and progesteron-receptor expression, and age. Ongoing trials should help verify if prognosis of lymph node negative patients could be improved by the use of anthracyclines in the adjuvant setting, as well as in lymph node positive patients. Regarding the treatment of metastatic disease, the availability of new drugs, like paclitaxel, docetaxel and vinorelbine, obtained good rates in terms of responses (50-80% and 40-60% in first and second line chemotherapy respectively), associated with a benefit in quality of life. Actually the clinical and biological research wants to identify the synergism between available drugs and new hormonal or cytotoxic molecules and to introduce new biological modulators of the response in the clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=0033362355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033362355&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0033362355

VL - 14

JO - Annali Italiani di Medicina Interna, Supplement

JF - Annali Italiani di Medicina Interna, Supplement

SN - 1122-0538

IS - 1

ER -